Celsion Corporation

1.05-0.0500-4.55%Vol 589.67K1Y Perf -8.76%
Jul 23rd, 2021 16:00 DELAYED
BID1.05 ASK1.07
Open1.08 Previous Close1.10
Pre-Market- After-Market1.07
 - -  0.02 1.90%
Target Price
4.00 
Analyst Rating
Strong Buy 1.00
Potential %
280.95 
Finscreener Ranking
★★★★+ —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★★★+     52.54
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★★★+     55.62
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Market Cap90.89M 
Earnings Rating
Neutral
Price Range Ratio 52W %
20.31 
Earnings Date
13th Aug 2021

Today's Price Range

1.051.10

52W Range

0.43053.48

5 Year PE Ratio Range

-1.60-0.7000

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.00%
1 Month
-15.32%
3 Months
-7.89%
6 Months
-23.36%
1 Year
-8.76%
3 Years
-64.41%
5 Years
-93.80%
10 Years
-99.60%

TickerPriceChg.Chg.%
CLSN1.05-0.0500-4.55
AAPL148.561.76001.20
GOOG2 756.3289.75003.37
MSFT289.673.53001.23
XOM57.04-0.0700-0.12
WFC44.59-0.4400-0.98
JNJ171.791.81001.06
FB369.7918.60005.30
GE12.710.01000.08
JPM150.64-0.2900-0.19
Financial StrengthValueIndustryS&P 500US Markets
8.20
8.40
0.07
0.11
-20.50
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
-
-4 570.20
-4 421.40
-4 270.20
-
RevenueValueIndustryS&P 500US Markets
375.00K
0.00
-2.78
-1.25
Earnings HistoryEstimateReportedSurprise %
Q01 2021--0.09-
Q04 2020-0.13-0.0561.54
Q03 2020-0.13-0.17-30.77
Q02 2020-0.14-0.18-28.57
Q01 2020-0.17-0.20-17.65
Q04 2019-0.20-0.1050.00
Q03 2019-0.30-0.2516.67
Q02 2019-0.33-0.2912.12
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.0873.33Positive
9/2021 QR-0.0773.08Positive
12/2021 FY-0.31--
12/2022 FY-0.30--
Next Report Date13th Aug 2021
Estimated EPS Next Report-0.08
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume589.67K
Shares Outstanding86.56M
Trades Count1.31K
Dollar Volume26.37M
Avg. Volume9.84M
Avg. Weekly Volume969.11K
Avg. Monthly Volume1.02M
Avg. Quarterly Volume1.54M

Celsion Corporation (NASDAQ: CLSN) stock closed at 1.05 per share at the end of the most recent trading day (a -4.55% change compared to the prior day closing price) with a volume of 594.10K shares and market capitalization of 90.89M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 29 people. Celsion Corporation CEO is Michael H. Tardugno.

The one-year performance of Celsion Corporation stock is -8.76%, while year-to-date (YTD) performance is 47.68%. CLSN stock has a five-year performance of -93.8%. Its 52-week range is between 0.4305 and 3.48, which gives CLSN stock a 52-week price range ratio of 20.31%

Celsion Corporation currently has a PE ratio of -1.90, a price-to-book (PB) ratio of 1.65, a price-to-sale (PS) ratio of 258.52, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -38.64%, a ROC of -47.45% and a ROE of -61.26%. The company’s profit margin is -%, its EBITDA margin is -4 421.40%, and its revenue ttm is $375.00 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Celsion Corporation, there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.08 for the next earnings report. Celsion Corporation’s next earnings report date is 13th Aug 2021.

The consensus rating of Wall Street analysts for Celsion Corporation is Strong Buy (1), with a target price of $4, which is +280.95% compared to the current price. The earnings rating for Celsion Corporation stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Celsion Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Celsion Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 36.77, ATR14 : 0.08, CCI20 : -94.21, Chaikin Money Flow : 0.05, MACD : -0.04, Money Flow Index : 37.87, ROC : -7.89, RSI : 38.18, STOCH (14,3) : 23.81, STOCH RSI : 0.23, UO : 55.42, Williams %R : -76.19), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Celsion Corporation in the last 12-months were: Donald Braun (Buy at a value of $5 350)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Celsion Corporation

Celsion Corp is active in the biotechnology market. The company acts as a drug developer with product candidates like ThermoDox, a heat-activated liposomal encapsulation of doxorubicin. It is in Phase III clinical trial for the treatment of primary liver cancer and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer. Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers.

CEO: Michael H. Tardugno

Telephone: +1 609 896-9100

Address: 997 Lenox Drive, Lawrenceville 08648, NJ, US

Number of employees: 29

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

46%54%

Bearish Bullish

69%31%

News

Stocktwits